SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
SCHEDULE 13G
(Rule
13d-102)
INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT
TO (s)
240.13d-1(b),
(c) AND (d) AND AMENDMENTS THERETO FILED
PURSUANT TO (s)
240.13d-2
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(Amendment No. 2)*
CoherusBioSciences, Inc.
(Name of Issuer)
Common Stock, par value $0.0001 per share
(Title of Class of Securities)
19249H103
(CUSIP Number)
May 20, 2024
(Date of Event which Requires Filing of this Statement)
Check the appropriate box todesignate the rule pursuant to which this Schedule
is filed:
Rule
13d-1(b)
Rule
13d-1(c)
Rule
13d-1(d)
* The remainder of this cover page shall be filled out for a reporting
person's initial filing on this formwith respect to the subject class
of securities, and for any subsequent amendment containing information
which would alter the disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be
deemed to be "filed" for the purpose of Section 18 of the SecuritiesExchange
Act of 1934 ("Act") or otherwise subject to the liabilities of that section of
the Act but shall be subject to all other provisions of the Act (however, see
the Notes).
-------------------------------------------------------------------------------
CUSIP No.19249H103 Page 2 of 9
1 NAMES OFREPORTING PERSONS
Temasek Holdings (Private) Limited
2 CHECK THE APPROPRIATE BOX IF A MEMBEROF A GROUP (SEE INSTRUCTIONS)
(a)(b)
3 SEC USE ONLY
4 CITIZENSHIP OR PLACE OFORGANIZATION
Republic of Singapore
NUMBER OF 5 SOLE VOTING POWER
SHARES
BENEFICIALLY 0
OWNED BY
EACH
REPORTING
PERSON
WITH:
6 SHARED VOTING POWER
6,220,552
7 SOLE DISPOSITIVE POWER
0
8 SHARED DISPOSITIVE POWER
6,220,552
9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
6,220,552
10 CHECK IF THE AGGREGATE AMOUNT IN ROW(9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
11 PERCENT OF CLASS REPRESENTED BY AMOUNTIN ROW (9)
5.4%
(1)
12 TYPE OF REPORTING PERSON (SEEINSTRUCTIONS)
HC
(1) Based on 114,725,740 shares of the Issuer's common stock outstanding
as of April 30, 2024, as setforth in the Issuer's (as defined
herein) quarterly report on Form 10-Q filed with the Securities
and Exchange Commission (the "Commission") on May 9, 2024.
-------------------------------------------------------------------------------
CUSIP No.19249H103 Page 3 of 9
1 NAMES OFREPORTING PERSONS
Fullerton Management Pte Ltd
2 CHECK THE APPROPRIATE BOX IF A MEMBEROF A GROUP (SEE INSTRUCTIONS)
(a)(b)
3 SEC USE ONLY
4 CITIZENSHIP OR PLACE OFORGANIZATION
Republic of Singapore
NUMBER OF 5 SOLE VOTING POWER
SHARES
BENEFICIALLY 0
OWNED BY
EACH
REPORTING
PERSON
WITH:
6 SHARED VOTING POWER
6,220,552
7 SOLE DISPOSITIVE POWER
0
8 SHARED DISPOSITIVE POWER
6,220,552
9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
6,220,552
10 CHECK IF THE AGGREGATE AMOUNT IN ROW(9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
11 PERCENT OF CLASS REPRESENTED BY AMOUNTIN ROW (9)
5.4%
(1)
12 TYPE OF REPORTING PERSON (SEEINSTRUCTIONS)
HC
(1) Based on 114,725,740 shares of the Issuer's common stock outstanding as of April 30, 2024, as
setforth in the Issuer's quarterly report on Form 10-Q filed with the Commission on May 9, 2024.
-------------------------------------------------------------------------------
CUSIP No.19249H103 Page 4 of 9
1 NAMES OFREPORTING PERSONS
Temasek Life Sciences Private Limited
2 CHECK THE APPROPRIATE BOX IF A MEMBEROF A GROUP (SEE INSTRUCTIONS)
(a)(b)
3 SEC USE ONLY
4 CITIZENSHIP OR PLACE OFORGANIZATION
Republic of Singapore
NUMBER OF 5 SOLE VOTING POWER
SHARES
BENEFICIALLY 0
OWNED BY
EACH
REPORTING
PERSON
WITH:
6 SHARED VOTING POWER
6,220,552
7 SOLE DISPOSITIVE POWER
0
8 SHARED DISPOSITIVE POWER
6,220,552
9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
6,220,552
10 CHECK IF THE AGGREGATE AMOUNT IN ROW(9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
11 PERCENT OF CLASS REPRESENTED BY AMOUNTIN ROW (9)
5.4%
(1)
12 TYPE OF REPORTING PERSON (SEEINSTRUCTIONS)
HC
(1) Based on 114,725,740 shares of the Issuer's common stock outstanding as of April 30, 2024, as
setforth in the Issuer's quarterly report on Form 10-Q filed with the Commission on May 9, 2024.
-------------------------------------------------------------------------------
CUSIP No.19249H103 Page 5 of 9
1 NAMES OFREPORTING PERSONS
V-Sciences Investments Pte Ltd
2 CHECK THE APPROPRIATE BOX IF A MEMBEROF A GROUP (SEE INSTRUCTIONS)
(a)(b)
3 SEC USE ONLY
4 CITIZENSHIP OR PLACE OFORGANIZATION
Republic of Singapore
NUMBER OF 5 SOLE VOTING POWER
SHARES
BENEFICIALLY 0
OWNED BY
EACH
REPORTING
PERSON
WITH:
6 SHARED VOTING POWER
6,220,552
7 SOLE DISPOSITIVE POWER
0
8 SHARED DISPOSITIVE POWER
6,220,552
9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
6,220,552
10 CHECK IF THE AGGREGATE AMOUNT IN ROW(9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
11 PERCENT OF CLASS REPRESENTED BY AMOUNTIN ROW (9)
5.4%
(1)
12 TYPE OF REPORTING PERSON (SEEINSTRUCTIONS)
CO
(1) Based on 114,725,740 shares of the Issuer's common stock outstanding as of April 30, 2024, as
setforth in the Issuer's quarterly report on Form 10-Q filed with the Commission on May 9, 2024.
-------------------------------------------------------------------------------
CUSIP No.19249H103 Page 6 of 9
Item 1(a). Name of Issuer:
Coherus BioSciences, Inc. (the "Issuer")
Item 1(b). Address of Issuer's Principal Executive Offices:
333 Twin Dolphin Drive, Suite 600, Redwood City, California 94065
Item 2(a). Name of Person Filing:
(i) Temasek Holdings (Private) Limited ("Temasek");
(ii) Fullerton Management Pte Ltd ("FMPL");
(iii) Temasek Life Sciences Private Limited ("TLS"); and
(iv) V-Sciences Investments Pte Ltd ("V-Sciences" and, together with Temasek, FMPL and TLS, the"Reporting Persons")
Item 2(b). Address of Principal Business Office or, if none, Residence:
The address of the principal business office of each Reporting Person is 60B
Orchard Road,
#06-18,
The Atrium@Orchard, Singapore 238891.
Item 2(c). Citizenship:
The citizenship of each of the Reporting Persons is the Republic of Singapore.
Item 2(d). Title of Class of Securities:
Common Stock, par value $0.0001 per share ("Common Stock").
Item 2(e). CUSIP Number:
19249H103
Item 3. If this statement is filed pursuant to (s)(s)240.13d-1(b) or 240.13d-2(b) or (c), check whether theperson filing is a:
Not applicable.
Item 4. Ownership.
(a) Amount beneficially owned:
As of May 20, 2024, V-Sciences directly owned 6,220,552 shares of the Issuer's
Common Stock. V-Sciences is a wholly-owned subsidiary ofTLS, which is a
wholly-owned subsidiary of FMPL, which is a wholly-owned subsidiary of
Temasek. Each of TLS, FMPL and Temasek, through the ownership described
herein, may be deemed to beneficially own the shares held by V-Sciences.
(b) Percent of class:
As of May 20, 2024: 5.4%
Thepercentage above is based on 114,725,740 shares of the Issuer's Common
Stock outstanding as of April 30, 2024, as set forth in the Issuer's quarterly
report on Form 10-Q filed with the Commission on May 9, 2024.
(c) Number of shares as to which the person has:
With respect to the shared power to vote, or to direct the vote, and to
dispose, or to direct the disposition of, the shares of theIssuer's Common
Stock, please see Item 4(a) above regarding qualifications as to beneficial
ownership.
As of May 20, 2024:
(i) Sole power to vote or to direct the vote:
0.
-------------------------------------------------------------------------------
CUSIP No.19249H103 Page 7 of 9
(ii) Shared power to vote or to direct the vote:
6,220,552.
(iii) Sole power to dispose or to direct the disposition of:
0.
(iv) Shared power to dispose or to direct the disposition of:
6,220,552.
Item 5. Ownership of Five Percent or Less of a Class.
If this statement is being filed to report the fact that as of the date hereof
the reporting person has ceased to be the beneficial owner ofmore than 5
percent of the class of securities, check the following .
Item 6. Ownership of More than Five Percent on Behalf of Another Person.
Not Applicable.
Item 7. Identification and Classification of the Subsidiary Which Acquired
the Security Being Reported on By theParent Holding Company.
Not Applicable.
Item 8. Identification and Classification of Members of the Group.
Not Applicable.
Item 9. Notice of Dissolution of Group.
Not Applicable.
Item 10. Certification.
By signing below I certify that, to the best of my knowledge and belief, the
securities referred to above were not acquired and are not heldfor the purpose
of or with the effect of changing or influencing the control of the issuer of
the securities and were not acquired and are not held in connection with or as
a participant in any transaction having that purpose or effect, other
thanactivities solely in connection with a nomination under (s) 240.14a-11.
-------------------------------------------------------------------------------
CUSIP No.19249H103 Page 8 of 9
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify
that the information set forth in this statement is true,complete and correct.
Dated: May 22, 2024 TEMASEK HOLDINGS (PRIVATE) LIMITED
By: /s/ Jason Norman Lee
Name : Jason Norman Lee
Title : Authorized Signatory
Dated: May 22, 2024 FULLERTON MANAGEMENT PTE LTD
By: /s/ Gregory Tan
Name : Gregory Tan
Title : Director
Dated: May 22, 2024 TEMASEK LIFE SCIENCES PRIVATE LIMITED
By: /s/ Lim Siew Lee Sherlyn
Name : Lim Siew Lee Sherlyn
Title : Director
Dated: May 22, 2024 V-SCIENCES INVESTMENTS PTE LTD
By: /s/ Khoo Ken Hui
Name : Khoo Ken Hui
Title : Director
-------------------------------------------------------------------------------
CUSIP No.19249H103 Page 9 of 9
LIST OF EXHIBITS
Exhibit No. Description
99.1 Joint Filing Agreement, dated as of May 22, 2024, by and among Temasek, FMPL, TLS and V-Sciences.
Exhibit 99.1
JOINT FILING AGREEMENT
The undersigned hereby agree that the statement on Schedule 13G initially
filed on August 31, 2017, as amended on February 7, 2020and May 22, 2024 (the
"Schedule 13G"), with respect to the Common Stock, par value $0.0001 per
share, of Coherus BioSciences, Inc. is, and any further amendments thereto
executed by each of us shall be, filed on behalf of each of uspursuant to and
in accordance with the provisions of Rule 13d-1(k)(1) under the Securities and
Exchange Act of 1934, as amended, and that this Agreement shall be included as
an exhibit to the Schedule 13G and each such amendment.
Each of the undersigned agrees to be responsible for the timely filing of the
Schedule 13G and any amendments thereto, and for thecompleteness and accuracy
of the information concerning such person contained therein; but none of them
is responsible for the completeness or accuracy of the information concerning
the other persons making the filing, unless such person knows orhas reason to
believe that such information is inaccurate. This Agreement may be executed in
any number of counterparts, all of which taken together shall constitute one
and the same instrument.
IN WITNESS WHEREOF, the undersigned hereby execute this Joint Filing Agreement
as of the 22nd day of May, 2024.
Dated: May 22, 2024 TEMASEK HOLDINGS (PRIVATE) LIMITED
By: /s/ Jason Norman Lee
Name : Jason Norman Lee
Title : Authorized Signatory
Dated: May 22, 2024 FULLERTON MANAGEMENT PTE LTD
By: /s/ Gregory Tan
Name : Gregory Tan
Title : Director
Dated: May 22, 2024 TEMASEK LIFE SCIENCES PRIVATE LIMITED
By: /s/ Lim Siew Lee Sherlyn
Name : Lim Siew Lee Sherlyn
Title : Director
Dated: May 22, 2024 V-SCIENCES INVESTMENTS PTE LTD
By: /s/ Khoo Ken Hui
Name : Khoo Ken Hui
Title : Director